(24/7 MARKET NEWS) – Ainos, Inc. (NASDAQ:AIMD) is higher after announcing the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2 (the “Study”).
Ainos trading at $1.97, up $0.59 (+42,75%), and 3.29 million shares, on the news. Its 52-week range is $1.248 to $18.00.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.